Efficacy of Combining Intravitreal Bevacizumab With Photodynamic Therapy Using Reduced Light Fluence Rate in Choroidal Neovascularization Secondary to Pathologic Myopia.
Overview
- Phase
- Phase 1
- Intervention
- Combination therapy "IVB + rf-PDT"
- Conditions
- Myopia
- Sponsor
- University of Campania "Luigi Vanvitelli"
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- BCVA improved
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a reduced (RF) light fluence rate, in choroidal neovascularization (CNV) secondary to pathologic myopia.
Detailed Description
In this retrospective interventional case series, 16 patients with myopic CNV were included. All patients were treated with 1.25 mg of intravitreal bevacizumab followed by RF-PDT (25 J/cm²), 2 days later. All patients were previously treated with IVB monotherapy and active leaking of CNV occurred 90 to 120 days after the treatment. Best-corrected visual acuity (BCVA-ETDRS), foveal thickness (FT) on optical coherence tomography (OCT), and fluorescein and indocyanine green angiographic (FA; ICG) findings were recorded. Follow-up evaluations were carried out for 12 months.
Investigators
Chiosi Flavia
Chiosi Flavia
University of Campania "Luigi Vanvitelli"
Eligibility Criteria
Inclusion Criteria
- •Myopic CNV, CNV leakage
Exclusion Criteria
- •CNV not associated with high myopia
- •No activity of CNV
Arms & Interventions
Bevacizumab and verteporfin
Intervention: Combination therapy "IVB + rf-PDT"
Outcomes
Primary Outcomes
BCVA improved
Time Frame: 6 months
Secondary Outcomes
- no CNV leakage(6 months)